Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-13.72M -	-42.28M 208.25%	-87.93M 107.97%	-198.38M 125.60%	49.27M 124.84%
depreciation and amortization		1K -	52K 5,100%	487K 836.54%	1.09M 123.41%
deferred income tax		1.00M -	121K 87.92%
stock based compensation	108K -	243K 125%	3.14M 1,190.53%	21.71M 592.41%	37.16M 71.14%
change in working capital	3.50M -	2.60M 25.83%	4.59M 76.80%	-1.64M 135.71%	-65.66M 3,901.28%
accounts receivables				-15.31M -	-24.74M 61.66%
inventory				-9.77M -	-73.13M 648.58%
accounts payables	1.28M -	1.42M 10.78%	670K 52.75%	1.85M 176.72%	15.88M 756.63%
other working capital	2.22M -	1.18M 46.90%	3.92M 232.35%	21.58M 449.81%	16.33M 24.33%
other non cash items	-583K -	1.74M 398.11%	5.23M 200.81%	-2.06M 139.33%	-9.94M 383.46%
net cash provided by operating activities	-10.69M -	-36.70M 243.38%	-74.80M 103.83%	-179.87M 140.47%	11.92M 106.63%
investments in property plant and equipment		-151K -	-353K 133.77%	-2.53M 615.58%	-1.24M 50.87%
acquisitions net			-3M -	236.46M 7,982.07%	-92.05M 138.93%
purchases of investments			-49.05M -	-415.87M 747.80%	-300.83M 27.66%
sales maturities of investments			3M -	179.41M 5,880.37%	394.12M 119.67%
other investing activites			3M -	-236.46M 7,982.07%	92.05M 138.93%
net cash used for investing activites		-151K -	-46.41M 30,632.45%	-238.99M 414.99%	92.05M 138.52%
debt repayment	-641K -	-16.82M 2,523.56%	-263K 98.44%	-1.64M 521.67%
common stock issued	27K -	30.01M 111,033.33%	135M 349.91%	432.45M 220.33%	6.86M 98.41%
common stock repurchased
dividends paid
other financing activites	1.28M -	33.63M 2,523.56%	23.77M 29.33%	977K 95.89%	-3.31M 439.30%
net cash used provided by financing activities	668K -	46.82M 6,909.43%	158.51M 238.52%	431.79M 172.41%	3.54M 99.18%
effect of forex changes on cash			13K -	-65K 600%	160K 346.15%
net change in cash	-10.02M -	9.97M 199.56%	37.31M 274.08%	12.87M 65.52%	107.67M 736.96%
cash at beginning of period	13.11M -	3.09M 76.42%	13.07M 322.71%	50.38M 285.58%	63.24M 25.54%
cash at end of period	3.09M -	13.07M 322.71%	50.38M 285.58%	63.24M 25.54%	170.92M 170.25%
operating cash flow	-10.69M -	-36.70M 243.38%	-74.80M 103.83%	-179.87M 140.47%	11.92M 106.63%
capital expenditure		-151K -	-353K 133.77%	-2.53M 615.58%	-1.24M 50.87%
free cash flow	-10.69M -	-36.85M 244.79%	-75.15M 103.95%	-182.40M 142.70%	10.68M 105.85%

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

5.19

22/11 21:00

Market Cap

361.25M

Beta: -

Volume Today

831.95K

Avg: -

Preview